Related Experiment Videos
CD105 is important for angiogenesis: evidence and potential applications
Sarah E Duff1, Chenggang Li, John M Garland
1Department of Pathology, Medical School, University of Manchester, M13 9PT, UK.
Summary
CD105 (endoglin) is a key protein in tumor blood vessel formation and a promising target for cancer therapy. Targeting CD105 shows potential for cancer imaging, prognosis, and treatment, particularly for solid tumors.
Area of Science:
- Oncology
- Vascular Biology
- Biochemistry
Background:
- Angiogenesis drives tumor growth and metastasis, making antiangiogenic therapy a promising cancer treatment strategy.
- CD105 (endoglin) is highly expressed on angiogenic endothelial cells and plays a crucial role in transforming growth factor-beta signaling.
- Tumor microvessel density (MVD) assessed by CD105 is an independent prognostic indicator, with higher MVD correlating to poorer survival.
Purpose of the Study:
- To explore the role of CD105 as a target for cancer imaging, prognosis, and therapy.
- To evaluate the diagnostic and therapeutic potential of anti-CD105 antibodies in preclinical models and human patients.
Main Methods:
- Immunohistochemistry to assess CD105 expression in tumor tissues.
- Evaluation of circulating CD105 levels as a biomarker for metastasis.
- In vivo studies using radiolabeled anti-CD105 antibodies for tumor imaging.
- Preclinical testing of anti-CD105 antibody conjugates (immunotoxins, immunoradioisotopes) for tumor growth suppression.
- Immunoscintigraphy in patients with renal cell carcinoma using labeled CD105 monoclonal antibody.
Main Results:
- CD105 is strongly expressed in tumor vasculature and its levels correlate with prognosis and metastasis.
- CD105 knockout studies demonstrate its essential role in angiogenesis.
- Radiolabeled anti-CD105 antibodies show rapid accumulation in tumors, enabling effective imaging.
- Anti-CD105 antibody conjugates demonstrated significant tumor growth suppression in murine models with minimal side effects.
- Immunoscintigraphy confirmed specific localization of labeled anti-CD105 mab in tumor endothelial cells of patients.
Conclusions:
- CD105 is a critical mediator of angiogenesis and a valuable biomarker for cancer prognosis.
- Targeting CD105 offers significant potential for developing novel imaging agents and therapeutics for various cancers.
- Anti-CD105 strategies show promise for improving cancer detection and treatment outcomes.